Aquestive Therapeutics, Inc. AQST EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Aquestive Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s EBITDA margin?
- Aquestive Therapeutics, Inc. (AQST) reported EBITDA margin of -110.1% in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Aquestive Therapeutics, Inc.'s EBITDA margin decreased by 47.4% year-over-year, from -74.7% to -110.1%.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s EBITDA margin has grown at a 13.0% compound annual growth rate (CAGR), from -86% to -158.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.